Log In Help Join The Motley Fool

Free Analysis Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

ImmunoGen (NASDAQ: IMGN)

$4.58

(-2.6%)

-$0.12

Price as of September 23, 2022, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ImmunoGen Returns vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
IMGN	-24.92%	-30.08%	-6.90%	-52%
S&P	-16.99%	+47.60%	+8.09%	+981%

ImmunoGen Company Info

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs.

News & Analysis

The Fool has written over 200 articles on ImmunoGen.

Featured Article

Is ImmunoGen Stock a Bargain After Dropping 39%?

It takes more than a price drop to make a bargain.

Alex Carchidi | Apr 1, 2022

Featured Article

Why Shares of ImmunoGen Jumped 20.3% in December

The biotech company that focuses on oncology drugs released news from a positive clinical trial regarding its lead drug.

Jim Halley | Jan 3, 2022

3 Under-the-Radar Biotech Stocks to Buy in 2022

Adria Cimino | Dec 11, 2021

They may deliver major gains down the road.

Why ImmunoGen Stock Is Flying High Today

George Budwell | Dec 1, 2021

The biotech is continuing to surge after after a late-stage win in treatment for advanced ovarian cancer.

Why ImmunoGen Stock Soared Today

Joe Tenebruso | Nov 30, 2021

The cancer-fighting specialist's new antibody treatment could be a gamechanger.

These 2 Nasdaq Biotechs Are Bucking the Market Downtrend

Dan Caplinger | Nov 30, 2021

Wall Street is having a bad day, but shareholders in these companies are celebrating.

How ImmunoGen Trounced Analysts' Q4 Revenue and Earnings Estimates

Keith Speights | Feb 12, 2021

The company can thank its partner, Jazz Pharmaceuticals.

Why ImmunoGen Stock Jumped Today

Keith Speights | May 20, 2020

Momentum is continuing from the biotech's positive pipeline update last week.

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

339%

S&P 500 Returns

109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor

Valuation

Earnings Transcripts

ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript

IMGN earnings call for the period ending June 30, 2022.

Motley Fool Transcribing | Jul 30, 2022

ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript

IMGN earnings call for the period ending March 31, 2022.

Motley Fool Transcribing | May 6, 2022

ImmunoGen (IMGN) Q4 2021 Earnings Call Transcript

IMGN earnings call for the period ending December 31, 2021.

Motley Fool Transcribing | Feb 25, 2022

ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript

IMGN earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Oct 29, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services